Supplementary figures
Summary: Forest plots for analysed network meta-analysis outcomes, including randomized-trial sensitivity analyses. File type: PNG.

Supplementary Figure S1. Urinary continence at 1 month. Primary analysis including all study designs; conventional RARP is the reference treatment.
Supplementary Figure S2. Urinary continence at 3 months. Primary analysis including all study designs; conventional RARP is the reference treatment.
Supplementary Figure S3. Urinary continence at 12 months. Primary analysis including all study designs; conventional RARP is the reference treatment.
Supplementary Figure S4. Overall positive surgical margins. Primary analysis including all study designs; conventional RARP is the reference treatment.
Supplementary Figure S5. Overall complications. Primary analysis including all study designs; conventional RARP is the reference treatment.
Supplementary Figure S6. Clavien–Dindo grade I–II complications. Primary analysis including all study designs; conventional RARP is the reference treatment.
Supplementary Figure S7. Clavien–Dindo grade III or higher complications. Primary analysis including all study designs; conventional RARP is the reference treatment.
Supplementary Figure S8. Operative time. Primary analysis including all study designs; conventional RARP is the reference treatment.
Supplementary Figure S9. Estimated blood loss. Primary analysis including all study designs; conventional RARP is the reference treatment.
Supplementary Figure S10. Immediate urinary continence. Primary analysis including all study designs; conventional RARP is the reference treatment.
Supplementary Figure S11. Urinary continence at 2 weeks. Primary analysis including all study designs; conventional RARP is the reference treatment.
Supplementary Figure S12. Urinary continence at 6 months. Primary analysis including all study designs; conventional RARP is the reference treatment.
Supplementary Figure S13. Blood transfusion. Primary analysis including all study designs; conventional RARP is the reference treatment.
Supplementary Figure S14. Console time. Primary analysis including all study designs; conventional RARP is the reference treatment.
Supplementary Figure S15. Length of hospital stay. Primary analysis including all study designs; conventional RARP is the reference treatment.
Supplementary Figure S16. Urinary continence at 3 months, randomized trials only.
Supplementary Figure S17. Overall positive surgical margins, randomized trials only.
Supplementary Figure S18. Overall complications, randomized trials only.